

Bin Wu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/149875/publications.pdf>

Version: 2024-02-01

131
papers

2,153
citations

304602

22
h-index

377752

34
g-index

135
all docs

135
docs citations

135
times ranked

2320
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma. , 2018, 6, 124.		89
2	Anti-proliferative and chemosensitizing effects of luteolin on human gastric cancer AGS cell line. Molecular and Cellular Biochemistry, 2008, 313, 125-132.	1.4	83
3	Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma. JAMA Network Open, 2021, 4, e210037.	2.8	81
4	Economic Evaluation of First-Line Treatments for Metastatic Renal Cell Carcinoma: A Cost-Effectiveness Analysis in A Health Resourceâ€™Limited Setting. PLoS ONE, 2012, 7, e32530.	1.1	78
5	Rac3 regulates breast cancer invasion and metastasis by controlling adhesion and matrix degradation. Journal of Cell Biology, 2017, 216, 4331-4349.	2.3	66
6	Cost-Effectiveness of Osimertinib for EGFR Mutationâ€™Positive Nonâ€™Small Cell Lung Cancer after Progression following First-Line EGFR TKI Therapy. Journal of Thoracic Oncology, 2018, 13, 184-193.	0.5	56
7	Cost-Effectiveness of Nucleoside Analog Therapy for Hepatitis B in China: A Markov Analysis. Value in Health, 2010, 13, 592-600.	0.1	54
8	Costs of Trastuzumab in Combination With Chemotherapy for HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: An Economic Evaluation in the Chinese Context. Clinical Therapeutics, 2012, 34, 468-479.	1.1	50
9	Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy. BMC Cancer, 2014, 14, 984.	1.1	50
10	Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China. Lung Cancer, 2019, 127, 84-89.	0.9	49
11	Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China. Oncotarget, 2017, 8, 9996-10006.	0.8	47
12	Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system. International Immunopharmacology, 2021, 95, 107498.	1.7	45
13	Influence of deep brain stimulation of the subthalamic nucleus on cognitive function in patients with Parkinsonâ€™s disease. Neuroscience Bulletin, 2014, 30, 153-161.	1.5	43
14	Cost-Effectiveness of Adding Rh-Endostatin to First-Line Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer in China. Clinical Therapeutics, 2011, 33, 1446-1455.	1.1	42
15	Cost-Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR-Mutation-Positive Non-Small Cell Lung Cancer. Oncologist, 2019, 24, 349-357.	1.9	41
16	Health state utilities in patients with advanced non-small-cell lung cancer in China. Journal of Comparative Effectiveness Research, 2018, 7, 443-452.	0.6	35
17	Predictive value of MTT assay as an in vitro chemosensitivity testing for gastric cancer: One institution's experience. World Journal of Gastroenterology, 2008, 14, 3064.	1.4	35
18	Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. JAMA Network Open, 2021, 4, e218065.	2.8	31

#	ARTICLE	IF	CITATIONS
19	Research about the optimal strategies for prevention and control of varicella outbreak in a school in a central city of China: based on an SEIR dynamic model. <i>Epidemiology and Infection</i> , 2020, 148, e56.	1.0	30
20	Subgroup Economic Analysis for Glioblastoma in a Health Resource-Limited Setting. <i>PLoS ONE</i> , 2012, 7, e34588.	1.1	29
21	Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis. <i>Cancer Communications</i> , 2020, 40, 743-745.	3.7	29
22	Acute Kidney Injury Associated With Remdesivir: A Comprehensive Pharmacovigilance Analysis of COVID-19 Reports in FAERS. <i>Frontiers in Pharmacology</i> , 2022, 13, 692828.	1.6	29
23	Modeling the impact of the 7-valent pneumococcal conjugate vaccine in Chinese infants: an economic analysis of a compulsory vaccination. <i>BMC Health Services Research</i> , 2014, 14, 56.	0.9	28
24	Prevention of renal failure in Chinese patients with newly diagnosed type 2 diabetes: A cost-effectiveness analysis. <i>Journal of Diabetes Investigation</i> , 2018, 9, 152-161.	1.1	28
25	Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592091600.	1.4	27
26	The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis. <i>Translational Lung Cancer Research</i> , 2020, 9, 1770-1784.	1.3	26
27	Cost-effectiveness of prevention and management of diabetic foot ulcer and amputation in a health resource-limited setting. <i>Journal of Diabetes</i> , 2018, 10, 320-327.	0.8	25
28	Construct and Criterion Validity of the Euro Qol-5D in Patients with Systemic Lupus Erythematosus. <i>PLoS ONE</i> , 2014, 9, e98883.	1.1	24
29	Economic analysis of <i>ALK</i> testing and crizotinib therapy for advanced non-small-cell lung cancer. <i>Pharmacogenomics</i> , 2016, 17, 985-994.	0.6	22
30	Treatment adherence and disease burden of individuals with rheumatic diseases admitted as outpatients to a large rheumatology center in Shanghai, China. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 1591-1601.	0.8	22
31	Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2291-2302.	0.9	22
32	RAS testing and cetuximab treatment for metastatic colorectal cancer: a cost-effectiveness analysis in a setting with limited health resources. <i>Oncotarget</i> , 2017, 8, 71164-71172.	0.8	22
33	Cost Effectiveness of Ceritinib and Alectinib Versus Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-small-cell Lung Cancer. <i>Clinical Drug Investigation</i> , 2020, 40, 183-189.	1.1	21
34	First-line treatments for advanced renal-cell carcinoma with immune checkpoint inhibitors: systematic review, network meta-analysis and cost-effectiveness analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592095019.	1.4	21
35	Sulodexide for treating venous leg ulcers. <i>The Cochrane Library</i> , 2016, 2016, CD010694.	1.5	19
36	A pharmacovigilance study of association between proton pump inhibitor and dementia event based on FDA adverse event reporting system data. <i>Scientific Reports</i> , 2021, 11, 10709.	1.6	19

#	ARTICLE	IF	CITATIONS
37	Cost-effectiveness of Different Strategies for Stroke Prevention in Patients with Atrial Fibrillation in a Health Resource-Limited Setting. <i>Cardiovascular Drugs and Therapy</i> , 2014, 28, 87-98.	1.3	18
38	Ticagrelor versus clopidogrel in East-Asian patients with acute coronary syndromes: a meta-analysis of randomized trials. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 281-291.	0.6	18
39	Cost-effectiveness of afatinib and erlotinib as second-line treatments for advanced squamous cell carcinoma of the lung. <i>Future Oncology</i> , 2018, 14, 2833-2840.	1.1	18
40	The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review. <i>Frontiers in Pharmacology</i> , 2019, 10, 1260.	1.6	18
41	Proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting system. <i>Scientific Reports</i> , 2021, 11, 3690.	1.6	18
42	Patient-caregiver agreement and test-retest reliability of the EQ-5D-Y-3L and EQ-5D-Y-5L in paediatric patients with haematological malignancies. <i>European Journal of Health Economics</i> , 2021, 22, 1103-1113.	1.4	18
43	A pocket-sized device automates multiplexed point-of-care RNA testing for rapid screening of infectious pathogens. <i>Biosensors and Bioelectronics</i> , 2021, 181, 113145.	5.3	18
44	Cost-Effectiveness Analysis of Camrelizumab Plus Chemotherapy vs. Chemotherapy Alone as the First-Line Treatment in Patients With IIIB Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Without EGFR and ALK Alteration from a Perspective of Health - Care System in China. <i>Frontiers in Pharmacology</i> , 2021, 12, 735536.	1.6	18
45	Cost-effectiveness of a 23-valent pneumococcal polysaccharide vaccine immunization programme for the elderly in Shanghai, China. <i>Vaccine</i> , 2016, 34, 6158-6165.	1.7	17
46	Cost-effectiveness of omalizumab for the treatment of inadequately controlled severe allergic asthma in Chinese children. <i>Journal of Asthma</i> , 2020, 57, 87-94.	0.9	17
47	Carbohydrates Used in Polymeric Systems for Drug Delivery: From Structures to Applications. <i>Pharmaceutics</i> , 2022, 14, 739.	2.0	16
48	Treatment of moderate rheumatoid arthritis with different strategies in a health resource-limited setting: a cost-effectiveness analysis in the era of biosimilars. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 20-6.	0.4	15
49	Clopidogrel Versus Aspirin in Patients with Recent Ischemic Stroke and Established Peripheral Artery Disease: An Economic Evaluation in a Chinese Setting. <i>Clinical Drug Investigation</i> , 2015, 35, 365-374.	1.1	14
50	An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China. <i>Medicine (United States)</i> , 2017, 96, e7445.	0.4	14
51	Cost-Effectiveness and Budget Impact Analysis of Apatinib for Advanced Metastatic Gastric Cancer from the Perspective of Health Insurance System. <i>Gastroenterology Research and Practice</i> , 2017, 2017, 1-7.	0.7	14
52	Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China. <i>Frontiers in Pharmacology</i> , 2019, 10, 480.	1.6	14
53	Adverse events identified by the global trigger tool at a university hospital: A retrospective medical record review. <i>Journal of Evidence-Based Medicine</i> , 2019, 12, 91-97.	0.7	14
54	Effectiveness and safety of adjunctive inhaled antibiotics for ventilator-associated pneumonia: A systematic review and meta-analysis of randomized controlled trials. <i>Journal of Critical Care</i> , 2021, 65, 133-139.	1.0	14

#	ARTICLE	IF	CITATIONS
55	A pharmacovigilance study of the association between tetracyclines and hepatotoxicity based on Food and Drug Administration adverse event reporting system data. <i>International Journal of Clinical Pharmacy</i> , 2022, 44, 709-716.	1.0	14
56	Interventions for reducing inflammation in familial Mediterranean fever. <i>The Cochrane Library</i> , 2015, , CD010893.	1.5	13
57	Cost-effectiveness analysis of routine 13-valent pneumococcal conjugate vaccinations in Chinese infants. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 1444-1452.	1.4	13
58	Cost-Effectiveness of Genomic Test-Directed Olaparib for Metastatic Castration-Resistant Prostate Cancer. <i>Frontiers in Pharmacology</i> , 2020, 11, 610601.	1.6	13
59	Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1528-1536.	2.3	13
60	A Novel Nanoprobe for Targeted Imaging and Photothermal/Photodynamic Therapy of Lung Cancer. <i>Langmuir</i> , 2022, 38, 1360-1367.	1.6	13
61	Duration and intensity of fluconazole for prophylaxis in preterm neonates: a meta-analysis of randomized controlled trials. <i>BMC Infectious Diseases</i> , 2016, 16, 312.	1.3	12
62	Cost Effectiveness of Daclatasvir Plus Asunaprevir Therapy for Chinese Patients with Chronic Hepatitis C Virus Genotype 1b. <i>Clinical Drug Investigation</i> , 2018, 38, 427-437.	1.1	12
63	Development and validation of a Health Policy Model of Type 2 diabetes in Chinese setting. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 749-763.	0.6	12
64	Validating the Chinese geriatric trigger tool and analyzing adverse drug event associated risk factors in elderly Chinese patients: A retrospective review. <i>PLoS ONE</i> , 2020, 15, e0232095.	1.1	12
65	Association Between Genetic Polymorphisms of Metabolic Enzymes and Azathioprine-Induced Myelosuppression in 1,419 Chinese Patients: A Retrospective Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 672769.	1.6	12
66	RAGE, LDL receptor, and LRP1 expression in the brains of SAMP8. <i>Neuroscience Letters</i> , 2009, 461, 100-105.	1.0	11
67	Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China. <i>BMC Health Services Research</i> , 2012, 12, 385.	0.9	11
68	Cost-Effectiveness of Different Strategies for the Prevention of Venous Thromboembolism After Total Hip Replacement in China. <i>Advances in Therapy</i> , 2017, 34, 466-480.	1.3	11
69	Interventions for reducing inflammation in familial Mediterranean fever. <i>The Cochrane Library</i> , 2018, 2018, CD010893.	1.5	11
70	Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non-small-cell Lung Cancer. <i>Frontiers in Pharmacology</i> , 2021, 12, 573852.	1.6	11
71	Age-Related Changes in P-Glycoprotein Expression in Senescence- Accelerated Mouse. <i>Current Aging Science</i> , 2009, 2, 187-192.	0.4	11
72	Pembrolizumab vs the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-Effectiveness Analysis. <i>Clinical Drug Investigation</i> , 2020, 40, 1137-1146.	1.1	10

#	ARTICLE	IF	CITATIONS
73	Strategies to Screen for Diabetic Retinopathy in Chinese Patients with Newly Diagnosed Type 2 Diabetes. <i>Medicine (United States)</i> , 2015, 94, e1989.	0.4	9
74	Different Strategies for the Treatment of Age-Related Macular Degeneration in China: An Economic Evaluation. <i>Journal of Ophthalmology</i> , 2016, 2016, 1-12.	0.6	9
75	Cost-Effectiveness of Primary Prevention with Statin Treatment for Chinese Patients with Type 2 Diabetes. <i>Advances in Therapy</i> , 2018, 35, 2214-2223.	1.3	9
76	Cost-effectiveness of Dabigatran Compared With Rivaroxaban for Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in China. <i>Clinical Therapeutics</i> , 2020, 42, 144-156.e1.	1.1	9
77	Ranibizumab versus Bevacizumab for Ophthalmic Diseases Related to Neovascularisation: A Meta-Analysis of Randomised Controlled Trials. <i>PLoS ONE</i> , 2014, 9, e101253.	1.1	9
78	Sex differences in immune-related adverse events with immune checkpoint inhibitors: data mining of the FDA adverse event reporting system. <i>International Journal of Clinical Pharmacy</i> , 2022, 44, 689-697.	1.0	9
79	Mapping the neck disability index to SF-6D in patients with chronic neck pain. <i>Health and Quality of Life Outcomes</i> , 2016, 14, 21.	1.0	8
80	Propofol induces excessive vasodilation of aortic rings by inhibiting protein kinase $\text{C}\hat{\text{I}}^{22}$ and $\hat{\text{I}}$, in spontaneously hypertensive rats. <i>British Journal of Pharmacology</i> , 2017, 174, 1984-2000.	2.7	8
81	Economic Evaluation of Letrozole for Early Breast Cancer in a Health Resource-Limited Setting. <i>BioMed Research International</i> , 2018, 2018, 1-8.	0.9	8
82	Cost-effectiveness of novel regimens for Chinese patients with chronic hepatitis C. <i>Current Medical Research and Opinion</i> , 2019, 35, 847-857.	0.9	8
83	A Caprini Risk Score-Based Cost-Effectiveness Analysis of Enoxaparin for the Thromboprophylaxis of Patients After Nonorthopedic Surgery in a Chinese Healthcare Setting. <i>Clinical Drug Investigation</i> , 2020, 40, 161-171.	1.1	8
84	Economic burden of patients with advanced non-small-cell lung cancer receiving nivolumab versus chemotherapy in China. <i>Immunotherapy</i> , 2020, 12, 245-254.	1.0	8
85	The Cost-Effectiveness of Lifestyle Interventions for Preventing Diabetes in a Health Resource-Limited Setting. <i>Journal of Diabetes Research</i> , 2020, 2020, 1-8.	1.0	8
86	Economic evaluation of dapagliflozin versus metformin in Chinese patients whose diabetes is inadequately controlled with diet and exercise. <i>Cost Effectiveness and Resource Allocation</i> , 2020, 18, 12.	0.6	7
87	Age at Initiation and Frequency of Screening to Prevent Esophageal Squamous Cell Carcinoma in High-risk Regions: an Economic Evaluation. <i>Cancer Prevention Research</i> , 2020, 13, 543-550.	0.7	7
88	CD36 expression in the brains of SAMP8. <i>Archives of Gerontology and Geriatrics</i> , 2013, 56, 75-79.	1.4	6
89	Comparative Assessment of Different Health Utility Measures in Systemic Lupus Erythematosus. <i>Scientific Reports</i> , 2015, 5, 13297.	1.6	6
90	The study on the early warning period of varicella outbreaks based on logistic differential equation model. <i>Epidemiology and Infection</i> , 2019, 147, e70.	1.0	6

#	ARTICLE	IF	CITATIONS
91	Determination of the ED95 of a single bolus dose of dexmedetomidine for adequate sedation in obese or nonobese children and adolescents. <i>British Journal of Anaesthesia</i> , 2021, 126, 684-691.	1.5	6
92	Immune Checkpoint Inhibitors Plus an Anti-VEGF Antibody as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	6
93	Cost Effectiveness of Apixaban and Enoxaparin for the Prevention of Venous Thromboembolism After Total Knee Replacement in China. <i>Clinical Drug Investigation</i> , 2016, 36, 1001-1010.	1.1	5
94	Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Insulin-naive Chinese Patients With Type 2 Diabetes. <i>Clinical Therapeutics</i> , 2019, 41, 445-455.e4.	1.1	5
95	Cost-effectiveness of intravitreal conbercept versus other treatments for wet age-related macular degeneration. <i>Annals of Translational Medicine</i> , 2020, 8, 939-939.	0.7	5
96	The risk of venous thromboembolism in cancer patients receiving chemotherapy: a meta-analysis with systematic review. <i>Annals of Translational Medicine</i> , 2021, 9, 277-277.	0.7	5
97	Analysis of adverse event of interstitial lung disease in men with prostate cancer receiving hormone therapy using the Food and Drug Administration Adverse Event Reporting System. <i>British Journal of Clinical Pharmacology</i> , 2023, 89, 440-448.	1.1	5
98	Cost-effectiveness analysis of vonoprazan versus proton pump inhibitors in the treatment of reflux esophagitis in China. <i>Annals of Translational Medicine</i> , 2022, 10, 480-480.	0.7	5
99	Health Economic Analysis of Antiplatelet Therapy for Acute Coronary Syndromes in the Context of Five Eastern Asian Countries. <i>Clinical Drug Investigation</i> , 2018, 38, 621-630.	1.1	4
100	Cost-effectiveness of Oral Regimens for Adolescents With Chronic Hepatitis C Virus Infection. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, e59-e65.	1.1	4
101	New Oral Anticoagulants for Thromboprophylaxis in Patients with Cancer Receiving Chemotherapy: An Economic Evaluation in a Chinese Setting. <i>Clinical Drug Investigation</i> , 2020, 40, 653-663.	1.1	4
102	Interventions for reducing inflammation in familial Mediterranean fever. <i>The Cochrane Library</i> , 2022, 2022, CD010893.	1.5	4
103	Cost-effectiveness analysis of double low-dose budesonide and low-dose budesonide plus montelukast among pediatric patients with persistent asthma receiving Step 3 treatment in China. <i>Journal of Medical Economics</i> , 2020, 23, 1630-1639.	1.0	3
104	Cost-utility of ticagrelor plus aspirin in diabetic patients with stable coronary artery disease. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 529-538.	1.4	3
105	Hepatitis B Infection Among Pregnant Women in China: A Systematic Review and Meta-Analysis. <i>Frontiers in Public Health</i> , 2022, 10, 879289.	1.3	3
106	Abcb1a and Abcb1b expression in senescence-accelerated mouse (SAM). <i>Neuroscience Letters</i> , 2009, 456, 34-38.	1.0	2
107	Exploration and practice of methods and processes of evidence-based rapid review on peer review of WHO EML application. <i>Journal of Evidence-Based Medicine</i> , 2015, 8, 222-228.	2.4	2
108	Development of an Empirically Calibrated Model of Esophageal Squamous Cell Carcinoma in High-Risk Regions. <i>BioMed Research International</i> , 2019, 2019, 1-9.	0.9	2

#	ARTICLE	IF	CITATIONS
109	Health-related quality of life among Chinese patients with Crohn's disease: a cross-sectional survey using the EQ-5D-5L. <i>Health and Quality of Life Outcomes</i> , 2022, 20, 62.	1.0	2
110	Immune-related adverse events in older adults: Data mining of the FDA Adverse Event Reporting System. <i>Journal of Geriatric Oncology</i> , 2022, , .	0.5	2
111	Cost-effectiveness analysis of cinacalcet for haemodialysis patients with moderate-to-severe secondary hyperparathyroidism in China: evaluation based on the EVOLVE trial. <i>BMJ Open</i> , 2020, 10, e034123.	0.8	1
112	Bevacizumab in addition to chemotherapy first-line for right-side metastatic colorectal cancer: A cost-effectiveness analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, 777-777.	0.8	1
113	Heparin and related substances for treating diabetic foot ulcers. <i>The Cochrane Library</i> , 0, , .	1.5	1
114	The feasibility and safety of early removal of nasogastric tube after total gastrectomy for gastric cancer. <i>Hepato-Gastroenterology</i> , 2013, 60, 387-9.	0.5	1
115	Î²-Actin: An Emerging Biomarker in Ischemic Stroke. <i>Cellular and Molecular Neurobiology</i> , 2023, 43, 683-696.	1.7	1
116	Long non-coding RNA TDRG1 aggravates colorectal cancer stemness by binding with miR-873a-5p to upregulate PRKAR2. <i>Environmental Toxicology</i> , 0, , .	2.1	1
117	Authors' reply re: Medical therapy for preventing recurrent endometriosis after conservative surgery: a cost-effectiveness analysis. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2018, 125, 504-504.	1.1	0
118	Response: Comments on "Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small Cell Lung Cancer after Progression following First-Line EGFR Tyrosine Kinase Inhibitor Therapy. <i>Journal of Thoracic Oncology</i> , 2018, 13, e84-e85.	0.5	0
119	Expanding Antiviral Prophylaxis During Pregnancy to Prevent Perinatal Hepatitis B Virus Infection: A Cost-effectiveness Study. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa137.	0.4	0
120	Cetuximab and bevacizumab in addition to chemotherapy first-line for left-side metastatic colorectal cancer: A cost-effectiveness analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, 732-732.	0.8	0
121	Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: A cost-effective analysis compared with conventional chemotherapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15531-e15531.	0.8	0
122	Development of trigger tools for detection of adverse drug events in Chinese geriatric inpatients using Delphi method. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO3-12-4.	0.0	0
123	The Investigation of Behavior Change in EEG Signals During Induction of Anesthesia. <i>International Journal of Pattern Recognition and Artificial Intelligence</i> , 0, , .	0.7	0
124	The cost-effectiveness of low-dose budesonide as a Step 2 treatment for pediatric asthma in China. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 1141-1151.	0.6	0
125	Heparin and Related Substances for Treating Diabetic Foot Ulcers: A Systematic Review and Meta-Analysis. <i>Frontiers in Endocrinology</i> , 2022, 13, 749368.	1.5	0
126	Patient Preference for Biologic Treatments of Psoriasis in the Chinese Setting. <i>Patient Preference and Adherence</i> , 2022, Volume 16, 1071-1084.	0.8	0

#	ARTICLE	IF	CITATIONS
127	Title is missing!. , 2020, 15, e0232095.		0
128	Title is missing!. , 2020, 15, e0232095.		0
129	Title is missing!. , 2020, 15, e0232095.		0
130	Title is missing!. , 2020, 15, e0232095.		0
131	The Impacts of Gradually Terminating Nonpharmaceutical Interventions for SARS-CoV-2: A Mathematical Modelling Analysis. Fundamental Research, 2022, , .	1.6	0